Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-Associated disease in a hamster model of infection

Infection and Immunity

Volumn 66, Issue 5, 1998, Pages 2018-2025

  Kink, John A ^a   Williams, Jim A ^a,b  

^a Ophidian Pharmaceuticals Inc   (United States)

^b BioNehraska   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITOXIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B;

ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE; COLON MUCOSA; DIARRHEA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; SYRIAN HAMSTER;

CLOSTRIDIUM DIFFICILE;

EID: 0031948840     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.5.2018-2025.1998     Document Type: Article

References (54)

1. Anand, A., and A. E. Glatt. 1993. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin. Infect. Dis. 17:109-113.
2. Barroso, L. A., S. Z. Wang, C. J. Phelps, J. L. Johnson, and T. D. Wilkins. 1990. Nucleotide sequence of Clostridium difficile toxin B. Nucleic Acids Res. 8:4004.
3. Bartlett, J. G. 1981. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea or colitis. Johns Hopkins Med. J. 149:6-9.
4. Bartlett, J. G. 1994. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin. Infect. Dis. 18:S265-S272.
5. Borriello, S. P., A. R. Welch, F. E. Barclay, and H. A. Davies. 1988. Mucosal association by Clostridium difficile in the hamster gastrointestinal tract. J. Med. Microbiol. 25:191-196.
6. Borriello, S. P., B. W. Wren, S. Hyde, S. V. Seddon, P. Sibbons, M. M. Krishna, S. Tabaqchali, S. Manek, and A. B. Price. 1992. Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect. Immun. 60:4192-4199.
7. Buggy, B. P., R. Fekety, and J. Silva. 1987. Therapy of relapsing Clostridium difficile-associated diarrhea with the combination of vancomycin and rifampin. J. Clin. Gastroenterol. 9:155-159.
8. Centers tor Disease Control and Prevention. 1993. Nosocomial enterococci resistant to vancomycin - United States, 1989. Morbid. Mortal. Weekly Rep. 42:597-599.
9. Centers for Disease Control and Prevention. 1995. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Morbid. Mortal. Weekly Rep. 44:1-13.
10. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal. Weekly Rep. 46:471-476.
11. Chang, T., J. G. Bartlett, S. L. Gorbach, and A. B. Onderdonk. 1978. Clin-damycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect. Immun. 20:526-529.
12. Corthier, G., M. C. Muller, T. D. Wilkins, D. Lyerly, and R. L'Haridon. 1991. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect. Immun. 59:1192-1995.
13. Dworczynski, A., B. Sokol, and F. Meisel-Mikolajczyk, 1991. Antibiotic resistance of Clostridium difficile isolates. Cytobios 65:149-153.
14. Fekety, R. 1997. Guidelines for the diagnosis and management of Clostridium difficile-associatcd diarrhea and colitis. Am. J. Gastroenterol. 92:739-750.
15. Fekety, R., and A. B. Shah. 1993. Diagnosis and treatment of Clostridium difficile colitis. JAMA 269:71-75.
16. Fekety, R., J. Silva, R. Tosbniwal, M. Allo, J. Armstrong, R. Browne, J. Ebright, and G. Rifkin. 1979. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev. Infect. Dis. 1:386-397.
17. Gorbach, S. L. 1987. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillius GG. Lancet ii:1519.
18. Hecht, J. R. 1989. Clostridium difficile colitis secondary to intravenous vancomycin. Dig. Dis. Sci. 34:148-149.
19. Jobe, B., A. Grasely, and K. Deveney. 1995. Clostridium difficile colitis: an increasing hospital acquired illness. Am. J. Surg. 169:480-483.
20. Just, I., J. Selzer, M. Wilm, C. von Eichel-Streiber, M. Mann, and K. Aktories. 1995. Glucosylation of rho proteins by Clostridium difficile toxin B. Nature 375:500-503.
21. Just, I., M. Wilm, J. Selzer, G. Rex, C. von Eichel-Streiber, M. Mann, and K. Aktories. 1995. The enterotoxin from Clostridium difficile (toxin A) monoglucosylates the rho proteins. J. Biol. Chem. 270:13932-13936.
22. Kelly, C. P., C. Pothoulakis, and J. T. LaMont. 1994. Clostridium difficile colitis. N. Engl. J. Mod. 330:257-262.
23. Kim, P. H., J. P. Iaconis, and R. D. Rolfe. 1987. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 55:2984-2992.
24. Kriven, H. C., G. F. Clark, D. F. Smith, and T. D. Wilkins. 1986. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Galα1-3Galβ1-4GlcNAc. Infect. Immun. 53:573-581.
25. Libby, J. M., B. S. Jortner, and T. D. Wilkins. 1982. Effects of the two toxins of Clostridium difficile antibiotic-associated cecitis in hamsters. Infect. Immun. 36:822-829.
26. Lyerly, D. M., E. F. Bostwick, S. B. Binion, and T. D. Wilkins. 1991. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect. Immun. 59:2215-2218.
27. Lyerly, D. M., H. C. Krivan, and T. D. Wilkins. 1988. Clostridium difficile: its disease and toxins. Clin. Microbiol. Rev. 1:1-18.
28. McFarland, L. V., C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer, R. A. Moyer, J. A. Welcher, K. E. Bowen, J. L. Cox, Z. Noorani, G. Harrington, M. Rubin, and D. Greenwald. 1994. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 217:1913-1918.
29. Nord, C. D., and C. Edlund. 1990. Impact of antimicrobial agents on the intestinal microflora. J. Chemother. 2:218-237.
30. Onderdonk, A. B., R. L. Cisneros, and J. G. Bartlett. 1980 Clostridium difficile in gnotobiotic mice. Infect. Immun. 28:277-282.
31. Polson, A., B. M. von Wechmar, and G. Fazakerley. 1980. Antibodies to proteins from yolk of immunized hens. Immunol. Commun. 9:495-514.
32. Pothoulakis, C., R. Sullivan, D. A. Melnick, G. Triadafilopoulos, A. S. Gadenne, T. Meshulam, and J. T. LaMont. 1988. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J. Clin. Invest. 81:1741-1745.
33. Rafferty, M. E., M. I. McCormick, L. H. Bopp, A. L. Baltch, M. George, R. P. Smith, C. Rheal, W. Ritz, and D. Schoonmaker. 1997. Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect. Control Hosp. Epidemiol. 18:342-344.
34. Riegler, M., R. Sedivy, C. Pothoulakis, G. Hamilton, J. Zacherl, G. Bischof, E. Cosentini, W. Feil, R. Schiessel, J. T. LaMont, and E. Wenzl. 1995. Clostridium difficile toxin B is more potent than toxin A in damaging human colonie epithelium in vitro. J. Clin. Invest. 95:2004-2011.
35. Riley, T. V. 1996. Antibiotic-associated diarrhoea: a costly problem. PharmacoEconomics 10:1-3.
36. Roberts, M. C., L. V. McFarland, P. Mullany, and M. E. Mulligan. 1994. Characterization of the genetic basis of antibiotic resistance in Clostridium difficile. J. Antimicrob. Chemother. 33:419-429.
37. Rocha, M. F., M. E. T. Maia, L. R. P. S. Bezerra, D. M. Lyerly, R. L. Guerrant, R. A. Ribeiro, and A. A. M. Lima. 1997. Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1β, tumor necrosis factor alpha, and leukotrienes. Infect. Immun. 65:2740-2746.
38. Rupnik, M., V. Braun, F. Soehn, M. Jane, M. Hofstetter, R. Laufenberg-Feldmann, and C. von Eichel-Streiber. 1997. Characterization of polymorphisms in the toxin A and B genes of Clostridium difficile. FEMS Microbiol. Lett. 148:197-202.
39. Sambrook, J., E. F. Fritisch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
40. Samore, M. H. 1993. Epidemiology of nosocomial Clostridium difficile infection. Compr. Ther. 19:151-156.
41. Sauerborn, M., and C. Eichel-Streiber. 1990. Nucleotide sequence of Clostridium difficile toxin A. Nucleic Acids Res. 18:1629-1630.
42. Schwan, A., S. Sjholins, U. Trottestam, and B. Aronsson. 1984. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal feces. Scand. J. Infect. Dis. 16:211-215.
43. Silva, J. 1988. Update on pseudomembranous colitis. West. J. Med. 151: 644-648.
44. Tedesco, F. J. 1982. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am. J. Gastroenterol. 77:220-221.
45. Tedesco, F. J., D. Gorden, and W. C. Fortson. 1985. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am. J. Gastroenterol. 80:867-868.
46. Thalley, B. S., and S. B. Carroll. 1990. Rattlesnake and scorpion antivenoms from the eggs of yolks of immunized hens. Bio/Technology 8:934-938.
47. Thalley, B. S., M. B. van Boldrik, S. B. Carroll, W. Tepp, B. R. Das Gupta, and D. C. Stafford. 1993. Development of an avian antitoxin to type A botulinum neurotoxin, p. 467-472. In B. R. Das Gupta (ed.). Botulinum and tetanus neurotoxins. Plenum Press. New York, N.Y.
48. Tvede, M., and J. Rask-Madsen. 1989. Bacteriothcrapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet i:1156-1160.
49. von Eichel-Streiber, C., R. Laufenberg-Feldmann, S. Sartingen, J. Schulz, and M. Sauerborn. 1992. Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol. Gen. Genet. 233:260-268.
50. von Eichel-Streiber, C., M. Sauerborn, and H. K. Kuramitsu. 1992. Evidence for a modular structure of the homologous repetitive C-terminal carbohydrate-binding sites of Clostridium difficile toxins and Streptococcus mutans glucosyltransferases. J. Bacteriol. 174:6707-6710.
51. Watanabe, T., K. Oshashi, K. Matsui, and T. Kubota. 1997. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus auraus. J. Antimicrob. Chemother. 39:471-476.
52. Wilcox, M. H., J. G. Cunniffe, C. Trundle, and C. Redpath. 1996. Financial burden of hospital-acquired Clostridium difficile infection. J. Hosp. Infect. 34:23-30.
53. Williams, J. A., J. A. Langeland, B. S. Thalley, J. B. Skeath, and S. B. Carroll. 1995. Expression of foreign proteins in E. coli using plasmid vectors and purification of specific polyclonal antibodies, p. 15-58. In D. M. Glover and B. D. Hames (ed.), DNA cloning: a practical approach, 2nd ed., vol. 2. Expression systems. Oxford University Press, Oxford, United Kingdom.
54. Wren, B. W., and S. Tabaqchali. 1987. Restriction endonuclease DNA analysis of Clostridium difficile. J. Clin. Microbiol. 25:2402-2404.